4/29/2014 9:32:45 AM
MARTINSRIED / MUNICH, Germany, April 29, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and The Moulder Center for Drug Discovery Research, a unit of Temple University's School of Pharmacy, Philadelphia, Pa., USA, today announced a strategic alliance focused on the discovery of new therapeutic antibodies. Under the terms of the agreement, the Moulder Center will receive access to MorphoSys's Ylanthia® technology for use in validating new disease-related targets and generating therapeutic antibody candidates. MorphoSys will receive an exclusive option to develop any resulting antibodies. Financial details of the agreement were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
comments powered by